Monopar Therapeutics (MNPR) announced that it has entered into an agreement with Alexion, AstraZeneca (AZN) Rare Disease for an exclusive worldwide license to ALXN-1840, a drug candidate for Wilson disease that Alexion has progressed through a Phase 3 clinical trial that met its primary endpoint. Monopar will be responsible for all future global development and commercialization activities.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MNPR:
- Monopar Therapeutics Unveils Promising Radiopharmaceutical Data
- Monopar Therapeutics presents data from radiopharma program based on MNPR-101
- Monopar Therapeutics Expands Portfolio with New Patent Filing
- Monopar files provisional patent covering therapeutic radiopharmaceuticals
- Monopar Therapeutics initiated with a Buy at Rodman & Renshaw